Following the intravenous administration of 370 MBq (10 mCi) of florbetapir F 18 to healthy volunteers, the drug was distributed throughout the body with less than

• 5% of the injected ¹⁸F radioactivity present in the blood by 20 minutes following administration, and
• 2% present in the blood by 45 minutes after administration.1

The estimated radiation-absorbed doses for an average adult from intravenous injection of florbetapir F 18 are shown in Estimated Radiation-Absorbed Dose of Florbetapir F 18 Injection. The organs with the highest radiation-absorbed doses were the

• gallbladder
• upper large intestine
• small intestine
• liver
• osteogenic cells
• lower large intestine, and
• urinary bladder.1,2

The effective dose resulting from a 370-MBq (10-mCi) dose of florbetapir F 18 is 7.0 mSv (0.7 rem) in an adult (19×370=7030 µSv=7.030 mSv=0.7030 rem).1,2

The use of a computed tomography (CT) scan to calculate attenuation correction for reconstruction of florbetapir F 18 images, as done in positron emission tomography (PET)/CT imaging, will add radiation exposure. The actual radiation dose is operator- and scanner-dependent. Diagnostic head CT scans result in radiation exposure of approximately 2 mSv. The total radiation exposure from florbetapir F 18 administration and subsequent scan on a PET/CT scanner is estimated to be 9 mSv.1

Amyvid® (Florbetapir F 18 Injection) for intravenous use, Lilly

The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).